SARS-CoV-2 vaccination and phase 1 cancer clinical trials

TA Yap, LL Siu, E Calvo, Martijn Lolkema, PM Lorusso, JC Soria, R Plummer, JS de Bono, J Tabernero, U Banerji

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
11 Downloads (Pure)
Original languageEnglish
Pages (from-to)298-301
Number of pages4
JournalThe Lancet Oncology
Issue number3
Publication statusPublished - Mar 2021

Bibliographical note

Funding Information:
We declare no competing interests related to the study, with full details of other competing interests listed in the appendix . TAY thanks the MD Anderson Cancer Center for support grant P30 CA016672 and the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at the MD Anderson Cancer Center for support grant 1U01 CA180964. RP, JSDB, and UB thank the Experimental Cancer Centre and National Institute of Health Biomedical Research Centre for infrastructural funding.

Research programs

  • EMC OR-01

Cite this